Corvus Pharmaceuticals, Inc. (CRVS)
| Market Cap | 113.93M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -44.39M |
| Shares Out | 29.50M |
| EPS (ttm) | -1.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $4.06 |
| Previous Close | $4.13 |
| Change ($) | -0.07 |
| Change (%) | -1.69% |
| Day's Open | 4.30 |
| Day's Range | 4.00 - 4.33 |
| Day's Volume | 257,518 |
| 52-Week Range | 1.74 - 5.98 |
Updated interim d ata from CPI-818 's p hase 1/1b c linical t rial provide evidence supporting its potential as a treatment for T cell lymphomas
Includes updated data from CPI-818 phase 1/1b trial and pre-clinical results supporting use in autoimmune lymphoproliferative syndrome (ALPS) Includes updated data from CPI-818 phase 1/1b tria...
Data shows CPI-006 provide d enhanced and prolonged polyclonal humoral immunity to SARS - CoV - 2
Data to be presented in a poster and an oral session “ Hot Topic Symposium : COVID-19 and Cancer ” at SITC
Company to host R&D Symposium webcast November 12, 2020 at 11:00 am ET to highlight COVID-19 program and provide updates on its cancer programs Company to host R&D Symposium webcast November 1...
10x Genomics acquired ReadCoor, a Boston developer of In Situ technologies, for $350 million.
Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) shares were sharply higher on Monday after the company announced updated data from its ongoing early-stage study in patients with COVID-19.
Angel ’s pipeline will feature Corvus’ three clinical-stage candidates – ciforadenant, CPI-006 and CPI-818 – and its preclinical BTK inhibitor program
Enrollment in first three cohorts complete; final cohort now enrolling with plans to initiate a pivotal study before year-end
Data is part of Genentech’s MORPHEUS umbrella program and covers patients with resistant/refractory NSCLC treated with ciforadenant in combination with atezolizumab
Dr. Mitchell adds significant experience in cancer care, research and healthcare delivery as the Company advances pipeline into later-stage clinical development Dr. Mitchell adds significant e...
Characterization of novel immunotherapy approach with CPI-006 and details of COVID-19 clinical trial results submitted for publication online at medRxiv.org
BURLINGAME, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the fo...
BURLINGAME, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the 202...
Provides Update on CPI-006 Phase 1 COVID-19 Study
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
VANCOUVER, British Columbia, July 16, 2020 (GLOBE NEWSWIRE) -- Corvus Gold Inc. (“Corvus Gold” or the “Company”) - (TSX: KOR, OTCQX: CORVF) announces it has received positive drilling result...
Corvus Pharmaceuticals (CRVS) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) made a big splash on Tuesday by announcing that it would initiate an early-stage immunotherapy study in patients with COVID-19.
Shares of Corvus (CRVS) rise as it commences a phase I study to investigate a novel immunotherapy approach for patients with COVID-19.
Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) watched the COVID-19 stock bump play out in Tuesday’s session as this company joins the ever-growing list of coronavirus stocks.
Shares of Corvus Pharmaceuticals Inc (NASDAQ: CRVS) are advancing strongly Tuesday following an announcement concerning its foray into COVID-19 treatment.
Shares of Corvus Pharmaceuticals Inc. CRVS, +77.73% soared 81.2% in trading on Tuesday after the company said it launched an open-label Phase 1 clinical trial testing an experimental monoclona...
Approach stimulates immune response by activating B cells to enhance antibody production
Elucidation of CD68 as a Downstream Target of Adenosine Refines Adenosine Gene Signature into a Practical Pathology Test Provides Opportunity to Further Enrich Patient Selection for Responders
Corvus (CRVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q1 2020 Results - Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q1 2020 Results - Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q4 2019 Results - Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q4 2019 Results - Earnings Call Transcript
Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT
BURLINGAME, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-st...
Corvus Pharmaceuticals: Turnaround In Progress, Multiple Readouts Ahead
Selective ITK inhibitor was well tolerated with demonstration of specific target occupancy Selective ITK inhibitor was well tolerated with demonstration of specific target occupancy
SITC presentation builds on data at ASCO in June, adding evidence supporting a new immuno-oncology approach with CPI-006 via activation of immune cells and the inhibition of adenosine produc...
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q3 2019 Results - Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q3 2019 Results - Earnings Call Transcript
Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT
CRVS stock price has reached cash value, giving no value to its three drugs currently in clinical trials.
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q2 2019 Results - Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q2 2019 Results - Earnings Call Transcript
The stock has gained 70% during the past month due to significant insider buying.
Shares have lost over a third of their value since my initial article.
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q1 2019 Results - Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q1 2019 Results - Earnings Call Transcript
Today, it is Corvus Pharmaceuticals that is in the spotlight as we take a deeper look at this small cap developmental concern.
About CRVS
Corvus Pharmaceuticals, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/2 clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and stimulate various immune cells, as well as Phase I clinical tr... [Read more...]
| Industry Biotechnology | IPO Date Mar 23, 2016 |
| CEO Richard Miller | Employees 52 |
| Stock Exchange NASDAQ | Ticker Symbol CRVS |
Analyst Forecasts
According to 5 analysts, the average rating for CRVS stock is "Strong Buy." The 12-month stock price forecast is 9.20, which is an increase of 126.60% from the latest price.